OverviewSuggest Edit

CureVac is a biotechnology company that is active in the field of messenger RNA (mRNA) technology. Using mRNA it is able to directly give the body the information it needs to fight disease. CureVac mainly focuses on three therapeutic areas: cancer immunotherapies, prophylactic vaccines, and protein delivery.

TypePrivate
Founded2000
HQTübingen, DE
Websitecurevac.com
Employee Ratings3.2

Latest Updates

Employees (est.) (May 2020)400(+4%)
Job Openings118
Revenue (FY, 2020)€48.9 M(+181%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at CureVac

Ingmar Hoerr

Ingmar Hoerr

Founder
Franz-Werner Haas

Franz-Werner Haas

CEO
Florian von der Mulbe

Florian von der Mulbe

Chief Production Officer & Co-Founder
Pierre Kemula

Pierre Kemula

Chief Financial Officer
Mariola Fotin-Mleczek

Mariola Fotin-Mleczek

CTO
Igor Splawski

Igor Splawski

CSO
Show more

CureVac Office Locations

CureVac has offices in Tübingen, Frankfurt am Main and Boston
Tübingen, DE (HQ)
Friedrich-Miescher-Straße 15
Frankfurt am Main, DE
Schumannstr. 27
Tübingen, DE
Paul-Ehrlich-Straße 15
Boston, MA, US
250 Summer St 3rd Fl
Show all (4)

CureVac Financials and Metrics

Summary Metrics

Founding Date

2000

CureVac total Funding

$1.1 b

CureVac latest funding size

$640 m

Time since last funding

2 years ago

CureVac investors

CureVac's latest funding round in July 2020 was reported to be $640 m. In total, CureVac has raised $1.1 b. CureVac's latest valuation is reported to be $1.5 b.
View all funding rounds

CureVac Revenue

CureVac's revenue was reported to be €48.87 m in FY, 2020
EUR

Revenue (Q2, 2022)

61.8m

Gross profit (Q2, 2022)

109.0m

Net income (Q2, 2022)

(409.8m)

EBITDA (Q2, 2022)

(395.1m)

EBIT (Q2, 2022)

(406.8m)

Market valuation

1.5b

Cash (30-Sept-2021)

1.1b

EV

439.0m
Annual
EURFY, 2018FY, 2019FY, 2020

Revenue

12.9m17.4m48.9m

Cost of goods sold

(9.1m)(16.1m)(2.7m)

Gross profit

4.5m6.9m70.3m

R&D expense

(40.6m)(42.8m)(89.9m)
Quarterly
EURQ1, 2019Q2, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2022Q2, 2022

Revenue

3.2m1.1m3.1m32.5m5.2m(29.3m)61.8m

Cost of goods sold

(4.7m)(7.0m)(2.4m)(3.1m)(2.0m)(33.6m)(19.5m)

Gross profit

(781.0k)(4.5m)2.7m33.0m7.4m(84.5m)109.0m

R&D expense

(7.5m)(5.3m)(6.9m)(7.2m)(34.6m)20.2m(256.5m)
Annual
EURFY, 2018FY, 2019FY, 2020

Cash

21.4m30.7m1.3b

Accounts Receivable

5.5m15.7m1.0m

Prepaid Expenses

2.2m1.7m40.1m

Inventories

3.0m6.2m14.5m
Quarterly
EURQ1, 2019Q2, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2022Q2, 2022

Cash

43.5m892.4m1.4b1.1b

Accounts Receivable

2.4m2.6m2.5m

Prepaid Expenses

20.0m168.2m

Inventories

5.4m1.4m62.9m140.9m
Annual
EURFY, 2018FY, 2019FY, 2020

Net Income

(71.1m)(100.1m)(129.8m)

Depreciation and Amortization

3.8m4.6m10.7m

Inventories

878.0k(3.2m)(8.3m)
Quarterly
EURQ1, 2019Q2, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2022Q2, 2022

Net Income

(21.3m)(23.8m)(407.9m)

Depreciation and Amortization

1.6m1.8m11.3m

Inventories

(1.4m)772.0k(143.6m)
EURFY, 2018

Revenue/Employee

53.3k
Show all financial metrics

CureVac Operating Metrics

Mar, 2020May, 2020

Patent Applications

500

Patents Issued

700233

Phase I Trials Products

33

Technology Partners

22
Show all operating metrics

CureVac Acquisitions / Subsidiaries

Company NameDateDeal Size
CureVac Inc.
CureVac Real Estate GmbH

CureVac Revenue Breakdown

Embed Graph

CureVac revenue breakdown by business segment: 100.0% from PHARMACEUTICAL BIOLOG/VACCINES

CureVac Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

CureVac Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

CureVac Online and Social Media Presence

Embed Graph

CureVac News and Updates

CureVac, GSK ink 'pandemic preparedness' agreement through 2029 with German government

Shares of CureVac were up 0.6% in premarket trading on Monday after the company and GlaxoSmithKline said they signed an agreement with the German government for pandemic preparedness that includes mRNA vaccines. As part of the agreement, Germany has access to CureVac's mRNA manufacturing until 202…

CureVac begins Phase 1 clinical trial for new COVID-19 vaccine

Shares of CureVac were up 1.2% in premarket trading on Wednesday after the company said it dosed the first participant in a Phase 1 clinical trial for the new mRNA COVID-19 vaccine it's developing with GlaxoSmithKline . The study is being conducted in the U.S. and is set to enroll 210 adults. The c…

Worldwide RNA Interference (RNAi) Drug Delivery Industry to 2027 - Players Include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals and CureVac Among Others

Dublin, March 08, 2022 (GLOBE NEWSWIRE) -- The "Worldwide RNA Interference (RNAi) Drug Delivery" report has been added to ResearchAndMarkets.com's offering. The global RNA interference (RNAi) drug delivery market reached a value of US$ 54.74 Billion in 2021. Looking forward, the publisher expects …

CureVac starts Phase 1 trial for experimental flu shot developed with GSK

Shares of CureVac gained 2.6% in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial assessing an experimental mRNA-based influenza vaccine it developed with GlaxoSmithKline . The open-label study plans to enroll 240 adults. CureVac had prev…

CureVac cites 'promising' data for its investigational cancer injection

Shares of CureVac gained 3.5% in premarket trading on Wednesday after the company shared what it called promising data for its experimental cancer shot in a Phase 1 clinical trial. The injection is being tested in 58 patients with advanced cutaneous melanoma, adenoid cystic carcinoma, and certain t…

CureVac stops development of its COVID-19 shot, will focus on new COVID-19 vaccine set for 2022

Shares of CureVac tumbled 9.6% in premarket trading on Tuesday after the German biopharmaceutical company said it will scrap development of its COVID-19 vaccine candidate and instead focus on developing second-generation mRNA shots against COVID-19 with GlaxoSmithKline . The existing purchase agree…
Show more

CureVac Blogs

[English only] CureVac Announces Voting Results of General Meeting

The post [English only] CureVac Announces Voting Results of General Meeting appeared first on CureVac.

[English only] Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV

The post [English only] Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV appeared first on CureVac.

CureVac Frequently Asked Questions

  • When was CureVac founded?

    CureVac was founded in 2000.

  • Who are CureVac key executives?

    CureVac's key executives are Ingmar Hoerr, Franz-Werner Haas and Florian von der Mulbe.

  • How many employees does CureVac have?

    CureVac has 400 employees.

  • What is CureVac revenue?

    Latest CureVac annual revenue is €48.9 m.

  • What is CureVac revenue per employee?

    Latest CureVac revenue per employee is €122.2 k.

  • Who are CureVac competitors?

    Competitors of CureVac include Stemirna, RNACure and RNAimmune.

  • Where is CureVac headquarters?

    CureVac headquarters is located at Friedrich-Miescher-Straße 15, Tübingen.

  • Where are CureVac offices?

    CureVac has offices in Tübingen, Frankfurt am Main and Boston.

  • How many offices does CureVac have?

    CureVac has 4 offices.